Roche: 'promising' early phase trial data in breast cancer
(CercleFinance.com) - Roche's ipatasertib has showed promising anti-tumour activity in triple-negative breast cancer in an early phase trial, the Swiss drugmaker said on Monday.
In a Phase Ib study evaluating the efficacy and safety of a combination of ipatasertib, Roche's Tecentriq and chemotherapy, the treatment demonstrated a confirmed objective response rate of 73%, the company said.
"We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer," said Sandra Horning, Roche's Chief Medical Officer.
Later this year, Roche will initiate a Phase III study investigating the combination of ipatasertib, Tecentriq, and chemotherapy as first-line therapy for locally advanced/metastatic triple-negative breast cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In a Phase Ib study evaluating the efficacy and safety of a combination of ipatasertib, Roche's Tecentriq and chemotherapy, the treatment demonstrated a confirmed objective response rate of 73%, the company said.
"We are enthusiastic about the potential of this combination in triple-negative breast cancer, an aggressive type of breast cancer," said Sandra Horning, Roche's Chief Medical Officer.
Later this year, Roche will initiate a Phase III study investigating the combination of ipatasertib, Tecentriq, and chemotherapy as first-line therapy for locally advanced/metastatic triple-negative breast cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.